Coates Laura C, Corp Nadia, van der Windt Danielle A, Soriano Enrique R, Kavanaugh Arthur
As part of the supplement series GRAPPA 2020, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards. L.C. Coates, MB ChB, PhD, National Institute for Health Research Clinician Scientist, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; N. Corp, PhD, D.A. van der Windt, PhD, Primary Care Centre Versus Arthritis, School of Medicine, Keele University, Staffordshire, UK; E.R. Soriano, MD, MSc, Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; A. Kavanaugh, MD, Division of Rheumatology Allergy and Immunology, University of California, San Diego, La Jolla, California, USA. LCC has received grant/research support from AbbVie, Amgen, Celgene, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, and UCB, and honoraria or consulting fees from AbbVie, Amgen, Biogen, Boehringer-Ingelheim, BMS, Celgene, Eli Lilly, Janssen, Medac, Novartis, Pfizer, and UCB. ERS has received grant/research support from AbbVie, BMS, Janssen, Novartis, Pfizer, Roche, and UCB, and honoraria or consulting fees from AbbVie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, Roche, Sanofi, and UCB. AK has received grant/research support from AbbVie, Amgen, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, and UCB, and honoraria and/or consulting fees from AbbVie, Boehringer-Ingelheim, BMS, Eli Lilly, Janssen, Medac, Novartis, Pfizer, and UCB. NC and DAvdW have no conflicts of interest. Address correspondence to Dr. A. Kavanaugh, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92037-0943, USA. Email:
J Rheumatol. 2021 Feb 15. doi: 10.3899/jrheum.201681.
Throughout 2020, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) has been working to update the GRAPPA treatment recommendations for psoriasis and psoriatic arthritis (PsA). The planned methodology for this update was published previously, and herein we provide an update on progress so far, including details of the systematic literature searches undertaken. GRAPPA is committed to regular updates of its treatment recommendations to incorporate the many significant therapeutic advances that have taken place in the PsA literature since the previous recommendation publication in 2015. The development and updating of treatment recommendations for optimal treatment approaches for patients with PsA has been an important mission of the GRAPPA since its inception. GRAPPA is currently finalizing domain-specific recommendations with an aim to produce updated treatment recommendations for publication in 2021.
在2020年全年，银屑病和银屑病关节炎研究与评估小组（GRAPPA）一直在努力更新GRAPPA关于银屑病和银屑病关节炎（PsA）的治疗建议。此次更新的计划方法已在之前发表，在此我们提供到目前为止的进展更新，包括所进行的系统文献检索的详细信息。GRAPPA致力于定期更新其治疗建议，以纳入自2015年上次建议发布以来PsA文献中出现的许多重大治疗进展。自成立以来，为PsA患者制定最佳治疗方法的治疗建议的制定和更新一直是GRAPPA的一项重要使命。GRAPPA目前正在敲定特定领域的建议，旨在制定更新后的治疗建议以便于2021年发表。
